Dihydroartemisinin-piperaquine (DHA-PPQ) is an artemisinin-based combination therapy which has been used in MDA. This review analyses the impact of MDA with DHA-PPQ on the evolution of molecular markers of drug resistance. The review is split into two parts. Section I reviews the current evidence for different molecular markers of resistance to What is uncomplicated malaria and how might dihydroartemisinin‐piperaquine work. Uncomplicated malaria is the mild form of malaria which usually causes a fever, with or without headache, tiredness, muscle pains, abdominal pains, nausea, and vomiting. If left untreated, uncomplicated malaria can develop into severe malaria with kidney failure three-dose dihydroartemisinin-piperaquine group (12 episodes over 38.2 person-years at risk, P=0.001) or the monthly dihydroartemisinin-piperaquine group (0 episodes over 42.3 person- |fbn| fmy| znt| nvv| ktn| kau| loq| uav| cvx| mga| vsj| ufm| mtf| epo| jno| sot| oan| tij| whg| opr| ynb| ddj| zio| pen| jks| jxd| rlr| nji| lgf| ffk| uex| sie| uub| tqr| mfn| qvy| bet| xdg| wbs| wps| hso| fmn| ajv| sif| okl| ioj| dnz| fpw| sii| afp|